Figure 6
Figure 6. Differential survival of thymic and peripheral T cells in the mutant mice and the underlying mechanism. (A) Bone marrow cells from Lck-Cre+-Crryflox/flox mice (CD45.2) and WT mice (CD45.1) were mixed at 1:1 ratio and transplanted into lethally irradiated WT or C3−/− recipients (n = 4 per group). After 2 months, the ratios of CD45.1/CD45.2 thymocytes (DN, DP, CD4 single positive, CD8 single positive), and peripheral (lymph node and blood) CD4+ or CD8+ T cells were determined by flow cytometry. CD45.1 T cells were enriched in the lymph nodes (LNs) and blood (BL) but not in the thymus of WT recipients. As expected, no enrichment was observed at any sites in C3−/− recipients. (B) Lck-Cre+-Crryflox/flox and Lck-Cre−-Crryflox/flox mice (n = 4 per group) were treated twice weekly with clodronate liposome (+) or control liposome (−) for 4 weeks, and blood CD4+ and CD8+ T-cell counts were monitored by flow cytometry. Clodronate liposome but not control liposome treatment time dependently increased blood CD4+ and CD8+ T-cell counts (NS, not statistically significant; *P < .05, Student t test). Clodronate-liposome treatment had no significant effect on blood T-cell counts in Lck-Cre−-Crryflox/flox mice. (C) Lck-Cre+-Crryflox/flox and Lck-Cre−-Crryflox/flox mouse thymocytes were labeled with CFSE, mixed at 1:1 ratio, and injected into different recipient mice (n = 2 per group). The ratios of Cre+/Cre− thymocytes (determined with the use of Crry as a marker among CFSE-positive cells) in the spleens of the recipient mice were determined 1 hour after cell injection. Some WT mice received clodronate-liposome or clodronate-PBS (control) treatment 24 hours before thymocyte transfer. (D) Same experimental procedure as in panel C except that the thymocytes were first incubated in 5% WT mouse serum at 37°C for 45 minutes before adoptive transfer. The top FACS histograms in panels C and D show C3 deposition levels on the thymocytes with (D) or without (C) ex vivo incubation in WT mouse serum. All values shown are mean plus or minus SEM.

Differential survival of thymic and peripheral T cells in the mutant mice and the underlying mechanism. (A) Bone marrow cells from Lck-Cre+-Crryflox/flox mice (CD45.2) and WT mice (CD45.1) were mixed at 1:1 ratio and transplanted into lethally irradiated WT or C3−/− recipients (n = 4 per group). After 2 months, the ratios of CD45.1/CD45.2 thymocytes (DN, DP, CD4 single positive, CD8 single positive), and peripheral (lymph node and blood) CD4+ or CD8+ T cells were determined by flow cytometry. CD45.1 T cells were enriched in the lymph nodes (LNs) and blood (BL) but not in the thymus of WT recipients. As expected, no enrichment was observed at any sites in C3−/− recipients. (B) Lck-Cre+-Crryflox/flox and Lck-Cre-Crryflox/flox mice (n = 4 per group) were treated twice weekly with clodronate liposome (+) or control liposome (−) for 4 weeks, and blood CD4+ and CD8+ T-cell counts were monitored by flow cytometry. Clodronate liposome but not control liposome treatment time dependently increased blood CD4+ and CD8+ T-cell counts (NS, not statistically significant; *P < .05, Student t test). Clodronate-liposome treatment had no significant effect on blood T-cell counts in Lck-Cre-Crryflox/flox mice. (C) Lck-Cre+-Crryflox/flox and Lck-Cre-Crryflox/flox mouse thymocytes were labeled with CFSE, mixed at 1:1 ratio, and injected into different recipient mice (n = 2 per group). The ratios of Cre+/Cre thymocytes (determined with the use of Crry as a marker among CFSE-positive cells) in the spleens of the recipient mice were determined 1 hour after cell injection. Some WT mice received clodronate-liposome or clodronate-PBS (control) treatment 24 hours before thymocyte transfer. (D) Same experimental procedure as in panel C except that the thymocytes were first incubated in 5% WT mouse serum at 37°C for 45 minutes before adoptive transfer. The top FACS histograms in panels C and D show C3 deposition levels on the thymocytes with (D) or without (C) ex vivo incubation in WT mouse serum. All values shown are mean plus or minus SEM.

Close Modal

or Create an Account

Close Modal
Close Modal